Therapeutic potential of manipulating VEGF splice isoforms in oncology

Area of Science:

• Molecular biology
• Oncology
• Ophthalmology

Background:

• Current anti-angiogenic therapies targeting VEGF-A have limitations including low response rates and side effects.
• These limitations may stem from a lack of specificity between pro- and anti-angiogenic isoforms and off-target effects of VEGF-A.
• VEGF-A plays crucial roles in cell survival and maintenance beyond angiogenesis.

Purpose of the Study:

• To explore an alternative anti-angiogenic strategy focusing on targeting VEGF-A mRNA splicing mechanisms.
• To investigate the potential of modulating splice site choice in VEGF-A mRNA for therapeutic benefit.
• To review recent evidence on the pharmacological targeting of splicing factors involved in VEGF-A production.

Main Methods:

• Review of recent scientific literature on VEGF-A splicing and its pharmacological modulation.
• Analysis of animal models demonstrating the efficacy of targeting splicing mechanisms in neovascularization.
• Exploration of upstream processes and oncogenes with antagonistic splice isoforms.

Main Results:

• Targeting VEGF-A mRNA splicing has shown effectiveness in animal models of ocular neovascularization.
• This approach offers potential for greater specificity compared to direct VEGF-A targeting.
• Simultaneous targeting of upstream oncogenes with antagonistic splice isoforms is also considered.

Conclusions:

• Modulating VEGF-A mRNA splicing presents a promising, more specific alternative to current anti-angiogenic therapies.
• This strategy may overcome limitations associated with targeting VEGF-A directly, including side effects.
• Pharmacological targeting of splicing factors offers a new avenue for developing anti-angiogenic treatments.